Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells

被引:0
|
作者
Mototsugu Oya
Masafumi Ohtsubo
Atsushi Takayanagi
Masaaki Tachibana
Nobuyoshi Shimizu
Masaru Murai
机构
[1] Keio University School of Medicine,Department of Urology
[2] Shinjuku-ku,Department of Molecular Biology
[3] Keio University School of Medicine,undefined
[4] Shinjuku-ku,undefined
来源
Oncogene | 2001年 / 20卷
关键词
renal cell carcinoma; TRAIL; NF-κB; IκBα; apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors. However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the absence of decoy receptors and the presence of death receptors. This suggested the existance of an inhibitory factor. We herein showed that NF-κB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-κB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of IκBα, a specific inhibitor of NF-κB, in TRAIL-sensitive cell lines with a low NF-κB activity result in constitutive activation of NF-κB and resistance to TRAIL-induced apoptosis. Adenoviral expression of a stable form of IκBα in the TRAIL-resistant cell lines induced apoptosis. These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-κB activity and TRAIL-resistant RCC with constitutively activated NF-κB. In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-κB appears to be a promising therapy.
引用
收藏
页码:3888 / 3896
页数:8
相关论文
共 50 条
  • [11] Molecular mechanisms of TRAIL-induced apoptosis of cancer cells
    LI Lianyun & SHU HongbingCollege of Life Sciences
    ChineseScienceBulletin, 2001, (09) : 707 - 709
  • [12] Mechanisms of resistance to TRAIL-induced apoptosis in cancer
    Zhang, LD
    Fang, BL
    CANCER GENE THERAPY, 2005, 12 (03) : 228 - 237
  • [13] Mechanisms of resistance to TRAIL-induced apoptosis in cancer
    Lidong Zhang
    Bingliang Fang
    Cancer Gene Therapy, 2005, 12 : 228 - 237
  • [14] TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention
    Manzoor Ahmad
    Yufei Shi
    Oncogene, 2000, 19 : 3363 - 3371
  • [15] Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis
    Ren, Yu
    Wang, Xue
    Huang, Shuaishuai
    Xu, Yangkai
    Weng, Guobin
    Yu, Rui
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [16] Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells
    Munshi, A
    McDonnell, TJ
    Meyn, RE
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (01) : 46 - 52
  • [17] Inhibition of MEK sensitizes gastric cancer cells to TRAIL-induced apoptosis
    Wu, P.
    Cheng, Y. W.
    Wang, J. Y.
    Zhang, X. D.
    Zhang, L. J.
    NEOPLASMA, 2014, 61 (02) : 136 - 143
  • [18] TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention
    Ahmad, M
    Shi, YF
    ONCOGENE, 2000, 19 (30) : 3363 - 3371
  • [19] Nuclear factor-κB, cancer, and apoptosis
    Bours, V
    Bentires-Alj, M
    Hellin, AC
    Viatour, P
    Robe, P
    Delhalle, S
    Benoit, V
    Merville, MP
    BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1085 - 1089
  • [20] In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity
    Wuchter, C
    Krappmann, D
    Cai, Z
    Ruppert, V
    Scheidereit, C
    Dörken, B
    Ludwig, WD
    Karawajew, L
    LEUKEMIA, 2001, 15 (06) : 921 - 928